Stockscreener 앱 받기
28.27
4.27%
-1.26
시간 외 거래:
28.01
-0.26
-0.92%
Travere Therapeutics Inc 주식(TVTX)의 최신 뉴스
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Exploring a 44.65% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
TVTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Total debt per share of Travere Therapeutics, Inc. – BOATS:TVTX - TradingView
Travere Therapeutics (TVTX) Is Up 7.4% After FILSPARI-Fueled Revenue Surge And Narrower LossesHas The Bull Case Changed? - simplywall.st
Travere Therapeutics, Inc. (TVTX) Stock Analysis: A 39% Upside Potential Sparks Investor Interest - DirectorsTalk Interviews
Travere Therapeutics (TVTX) CEO sells 60,000 shares in 10b5-1 trade - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Travere Therapeutics (TVTX), Insmed (INSM) - The Globe and Mail
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory - Finviz
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 - Finviz
Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms (NASDAQ:TVTX) - Seeking Alpha
A Look At Travere Therapeutics (TVTX) Valuation After Q4 Earnings Beat And FILSPARI Regulatory Progress - Yahoo Finance
Assessing Travere Therapeutics (TVTX) Valuation After Strong Earnings Beat And Pipeline Progress - Sahm
Bank of America Securities Sticks to Their Buy Rating for Travere Therapeutics (TVTX) - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to Buy - MarketBeat
Travere outlines FILSPARI-driven growth and new FSGS milestone as 2026 begins - MSN
Travere Therapeutics Earnings Call Shows Growth Amid Risks - TipRanks
TVTX (NASDAQ): Affiliate files Form 144 to sell 60,000 shares - Stock Titan
How liquid is Travere Therapeutics Inc. stockJuly 2025 Volume & Daily Chart Pattern Signals - mfd.ru
Travere Therapeutics (NASDAQ:TVTX) Shares Down 5.4%Should You Sell? - MarketBeat
Travere Therapeutics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Travere Therapeutics, Inc. (NASDAQ:TVTX) Q4 2025 Earnings Call Transcript - Insider Monkey
Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights - GuruFocus
Decoding Travere Therapeutics Inc (TVTX): A Strategic SWOT Insig - GuruFocus
Travere Therapeutics Q4 Earnings Call Highlights - MarketBeat
Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results - BioSpace
TVTX: FILSPARI drove record revenue and patient growth in 2025, with strong outlook for 2026 - TradingView
Travere (TVTX) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo Finance
Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates - Yahoo Finance
Travere Therapeutics, Inc. SEC 10-K Report - TradingView
TVTX: 2025 revenue surged to $490.7M on FILSPARI growth; net loss narrowed and pipeline advanced - TradingView
Travere Therapeutics (NASDAQ:TVTX) Announces Quarterly Earnings Results, Beats Estimates By $0.42 EPS - MarketBeat
Travere Therapeutics posts surprise Q4 profit; Shares slip 5% on revenue miss - Investing.com Canada
Travere: Fourth Quarter Financial Results Overview - Bitget
Travere: Q4 Earnings Snapshot - KVUE
Earnings Flash (TVTX) Travere Therapeutics, Inc. Posts Q4 Adjusted EPS $0.37 per Share, vs. FactSet Est of $0.38 - marketscreener.com
Travere Therapeutics Q4 Earnings Report: What Investors Need to Know - Benzinga
Travere Therapeutics faces earnings test amid FSGS approval delay By Investing.com - Investing.com UK
Travere Therapeutics faces earnings test amid FSGS approval delay - Investing.com Australia
Stocks with rising relative price strength: Travere Therapeutics - MSN
Earnings Outlook For Travere Therapeutics - Benzinga
Aberdeen Group plc Acquires 70,791 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics, Inc. (TVTX) Positioned for Long-Term Growth in Rare Disease Market - Finviz
Palisades Investment Initiated a Position in Travere Therapeutics Worth Over $5 Million. Is the Stock a Buy? - AOL.com
Travere Therapeutics, Inc. (TVTX) Stock Analysis: Unpacking A 52.25% Potential Upside - DirectorsTalk Interviews
How New Filspari Reviews And Price Targets Are Rewriting The Story For Travere Therapeutics (TVTX) - Yahoo Finance
Is Travere Therapeutics (TVTX) Still Attractive After Recent Share Price Volatility? - Yahoo Finance
Precision Trading with Travere Therapeutics Inc. (TVTX) Risk Zones - Stock Traders Daily
15 Innovative Healthcare Stocks to Buy According to Analysts - Insider Monkey
Travere Therapeutics Targets April FSGS FILSPARI Decision as IgAN Sales Accelerate, HCU Trial Restarts - MarketBeat
Can Travere Therapeutics Inc. be recession proofJuly 2025 Trade Ideas & Weekly High Conviction Ideas - mfd.ru
5.71%
0.02%
자본화:
|
볼륨(24시간):